The aim of this tumour board is to give patients access to new, targeted therapies through the use of new diagnostic molecular genetic and pathological procedures (e.g. sequencing of the tumour genome), either as part of clinical trials or in the form of individual treatment trials. This applies in particular, but not exclusively, to patients with a lack of approved treatment options. Here, the decision of the tumour board can be helpful in submitting an application to the patient's health insurance company for the costs of the therapy to be covered. On the other hand, patients for whom germline testing for a genetic disposition has been considered or carried out can be presented to the board. This applies in particular to the question of rare tumour disposition syndromes or if therapy recommendations are derived from such germline testing.